HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masayoshi Asano Selected Research

CS-2100

5/2012Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masayoshi Asano Research Topics

Disease

1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022
1Breast Neoplasms (Breast Cancer)
07/2017
1Triple Negative Breast Neoplasms
07/2017
1Obesity
01/2016
1Arthritis (Polyarthritis)
05/2012
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
05/2012
1Animal Disease Models
05/2012

Drug/Important Bio-Agent (IBA)

1Messenger RNA (mRNA)IBA
01/2022
1Transcription Factors (Transcription Factor)IBA
01/2022
1taxaneIBA
07/2017
1Albumin-Bound PaclitaxelFDA Link
07/2017
1Trastuzumab (Herceptin)FDA Link
07/2017
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
07/2017
1Epidermal Growth Factor (EGF)IBA
07/2017
1Phenobarbital (Luminal)FDA Link
07/2017
1Epirubicin (Ellence)FDA LinkGeneric
07/2017
1AnthracyclinesIBA
07/2017
1Carboxylic AcidsIBA
01/2016
1EstersIBA
01/2016
1CS-2100IBA
05/2012

Therapy/Procedure

1Neoadjuvant Therapy
07/2017